Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

To Shareholders,

May 9, 2024

Company Name Renascience Inc. Representative: Koji Naito, President & CEO (Code: 4889 TSE Growth) For inquiries, please contact Administration Dept.

Notice of Extraordinary Loss (Impairment Loss)

The Company announces that it has recorded the following extraordinary loss (impairment loss) for the fourth quarter of the fiscal year ending March 31, 2024 (January 1, 2024, to March 31, 2024).

1. Extraordinary loss (Impairment loss)

In the fourth quarter of the fiscal year ending March 31, 2024 (January 1, 2024, to March 31, 2024), the Company recognized impairment loss of 4,502 thousand yen as extraordinary loss for the Company's fixed assets in accordance with the "Accounting Standard for Impairment of Fixed Assets".

2. Impact on business performance

This matter is reflected in the "Financial Results for the Fiscal Year Ended March 31, 2024 [Japanese GAAP] (Nonconsolidated)" released today.

End